Isocarboxazid has 21 known drug interactions based on U.S. FDA drug labeling data. Of these, 20 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Desvenlafaxine, Desvenlafaxine Er, Desvenlafaxine Succinate. Patients taking Isocarboxazid should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 21
- Contraindicated
- 20
- Major
- 1
Contraindicated (20)
- Isocarboxazid + Desvenlafaxine— Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping MAOI.
- Isocarboxazid + Desvenlafaxine Er— Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders…
- Isocarboxazid + Desvenlafaxine Succinate— Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI intended to treat psychiatric disorders …
- Isocarboxazid + Dexmethylphenidate Hydrochloride— Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, ao…
- Isocarboxazid + Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine Sulfate— MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes…
- Isocarboxazid + Dextroamphetamine Sulfate— MAOI concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, myocardial infarcti…
- Isocarboxazid + Duloxetine— Concomitant use increases risk of serotonin syndrome. Use of isocarboxazid with duloxetine or within 5 days of stopping …
- Isocarboxazid + Levomilnacipran Hydrochloride— MAOI that increases risk of serotonin syndrome when used with levomilnacipran. Contraindicated use.
- Isocarboxazid + Methylphenidate Hydrochloride— Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, an…
- Isocarboxazid + Methylphenidate Hydrochloride Extended Release— Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, ao…
- Isocarboxazid + Mirtazapine— Concomitant use increases risk of serotonin syndrome. Mirtazapine is contraindicated in patients taking MAOIs.
- Isocarboxazid + Opicapone— Non-selective MAO inhibitor that inhibits catecholamine metabolism. Concomitant use may increase risk of arrhythmias, in…
- Isocarboxazid + Paroxetine— MAOI that increases risk of serotonin syndrome when combined with paroxetine. Paroxetine is contraindicated.
- Isocarboxazid + Paroxetine Hydrochloride— Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
- Isocarboxazid + Paroxetine Hydrochloride Hemihydrate— Concomitant use increases risk of serotonin syndrome.
- Isocarboxazid + Rizatriptan Benzoate— Nonselective MAO inhibitor contraindicated with rizatriptan due to increased plasma concentrations and potential for ser…
- Isocarboxazid + Sertraline— Concomitant use increases risk of serotonin syndrome. Sertraline is contraindicated in patients taking MAOIs.
- Isocarboxazid + Sertraline Hydrochloride— Concomitant use of MAOI isocarboxazid with sertraline hydrochloride increases risk of serotonin syndrome.
- Isocarboxazid + Trazodone Hydrochloride— Concomitant use increases risk of serotonin syndrome. Trazodone is contraindicated in patients taking MAOIs.
- Isocarboxazid + Vortioxetine— Concomitant use with MAOIs increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping…
Major (1)
- Isocarboxazid + Dopamine Hydrochloride— Inhibition of MAO prolongs and potentiates dopamine effects, potentially resulting in severe hypertension and cardiac ar…